There is more on this im still chasing links ....
Novartis in talks to buy stem-cell firm for up to $600M
Mar 18 2014, 09:01 ET
Novartis (NVS) is in advanced negotiations to acquire Israeli stem-cell treatments developer Gamida-Cell for up to $600M, Israel's Globes reports.
Novartis would pay hundreds of millions of dollars up front and the rest in milestones for the company, which develops therapies for a variety of conditions, including blood cancers and solid tumors.
Gamida shareholders Elbit Medical and Clal Biotechnology confirmed that a sizable offer had been made, but didn't disclose the suitor. Another investor is Teva (TEVA).
While talks are advanced, Gamida hasn't ruled out the prospect of an IPO in New York instead, although the firm's valuation in a listing would be lower.....V
- Forums
- ASX - By Stock
- MSB
- stem celll ready to rock..
stem celll ready to rock..
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B |
Open | High | Low | Value | Volume |
$1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 26808 | $1.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 16001 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 26808 | 1.440 |
2 | 28628 | 1.435 |
8 | 68533 | 1.430 |
5 | 155422 | 1.425 |
4 | 32112 | 1.420 |
Price($) | Vol. | No. |
---|---|---|
1.445 | 16001 | 1 |
1.450 | 4515 | 1 |
1.455 | 6500 | 1 |
1.460 | 45215 | 3 |
1.465 | 36008 | 2 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online